Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ · Healthcare
Lexicon Pharmaceuticals, Inc. Income Statement 2009–2025
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||||
| Revenue | 49.8M | 6.0M | 1.1M | 0 | 0 | 23.4M | 32.3M | 26.6M | 15.9M | 0 | 130.0M | 22.9M | 2.2M | 1.1M | 1.8M | 4.9M | 10.7M |
| Gross Profit | 49.5M | 5.4M | 1.0M | 0 | 0 | 21.5M | 29.1M | 24.1M | 14.0M | 0 | 130.0M | — | — | — | — | — | — |
| Profitability | |||||||||||||||||
| Operating Income | -48.9M | -197.1M | -171.8M | -100.8M | -87.1M | -47.8M | 141.4M | -103.3M | -130.6M | -127.2M | 1.5M | -100.4M | -102.4M | -108.4M | -114.1M | -95.7M | -90.0M |
| EBITDA | -48.3M | -196.6M | -171.2M | -100.3M | -86.8M | -44.9M | 145.1M | -99.6M | -127.2M | -125.1M | 2.2M | -98.4M | -99.5M | -104.2M | -109.2M | -90.3M | -83.8M |
| Net Income | -50.3M | -200.4M | -177.1M | -101.9M | -87.8M | -58.6M | 130.1M | -120.5M | -123.0M | -131.4M | -4.7M | -100.3M | -104.1M | -110.2M | -116.2M | -101.8M | -82.8M |
| Per Share Data | |||||||||||||||||
| EPS (diluted) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Shares Outstanding (dil.) | 363M | 320M | 221M | 166M | 146M | 111M | 117M | 106M | 105M | — | — | — | — | — | — | — | — |
Lexicon Pharmaceuticals, Inc. Income Statement — FAQ
Lexicon Pharmaceuticals, Inc. (LXRX) income statement over the last 17 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see LXRX's income statement history?
The chart and table above show Lexicon Pharmaceuticals, Inc.'s income statement by year and by quarter, including the growth rate.